Pulmonary Disease, Chronic Obstructive — Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Citation(s)
Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)